MedTrace Logo

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

NCT00466284 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2007-04-27

No results posted yet for this study

Summary

A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated.

STUDY OBJECTIVES

Primary: Objective response rate

Secondary: Progression free survival, Overall survival and Safety of Tarceva

Conditions

Interventions

DRUG

Tarceva (erlotinib)

Sponsors & Collaborators

  • Grupo Gallego de Cancer de Pulmon

    lead OTHER

Principal Investigators

  • Joquin Casal, MD · GGCP

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466284 on ClinicalTrials.gov